Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**8-Chlorotheophylline** is a stimulant drug of the xanthine chemical class with physiological effects similar to caffeine. Its primary use is as a component of the antiemetic drug dimenhydrinate (marketed as Dramamine and Gravol), where it is combined in a salt form with diphenhydramine. The stimulant properties of 8-chlorotheophylline are intended to counteract the drowsiness caused by diphenhydramine’s antihistaminic activity in the central nervous system. Mechanistically, its effects are mainly attributed to antagonism at adenosine receptors (notably A2a), leading to increased neuronal excitation. While classified as a xanthine stimulant like caffeine or theophylline, it does not cross the blood-brain barrier well and generally does not produce significant locomotor stimulation in animal models[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-Chlorotheophylline.